Future oncology (London, England), 2020-11, Vol.16 (32), p.2595-2609
2020
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Titel
- Trastuzumab emtansine: a game changer in HER2-positive early breast cancer
- Ist Teil von
- Future oncology (London, England), 2020-11, Vol.16 (32), p.2595-2609
- Ort / Verlag
- England: Future Medicine Ltd
- Erscheinungsjahr
- 2020
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- Trastuzumab emtansine (T-DM1), given postoperatively for 14 cycles to patients with human epidermal growth factor receptor 2-positive (HER2-positive) early breast cancer (EBC) who failed to achieve a pathological complete response after standard chemotherapy and HER2 blockade, represents probably the greatest progress in the management of this aggressive form of breast cancer since the adjuvant trastuzumab pivotal trials. This article addresses the rationale behind the conception of the KATHERINE trial, T-DM1’s structure and pharmacokinetics data, clinical efficacy data of the KATHERINE trial and of other EBC trials with T-DM1, safety aspects, implications of the KATHERINE trial results to clinical practice and future perspectives in the management of HER2-positive EBC.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 1479-6694eISSN: 1744-8301DOI: 10.2217/fon-2020-0219Titel-ID: cdi_proquest_journals_2473446915
- Format
- –
- Schlagworte
- Ado-Trastuzumab Emtansine - administration & dosage, Ado-Trastuzumab Emtansine - adverse effects, Ado-Trastuzumab Emtansine - therapeutic use, Antibodies, Antineoplastic Agents, Immunological - administration & dosage, Antineoplastic Agents, Immunological - adverse effects, Antineoplastic Agents, Immunological - therapeutic use, Antineoplastic Combined Chemotherapy Protocols - adverse effects, Antineoplastic Combined Chemotherapy Protocols - therapeutic use, Biomarkers, Tumor, Breast cancer, Breast Neoplasms - drug therapy, Breast Neoplasms - metabolism, Cancer therapies, Chemotherapy, Clinical trials, Clinical Trials as Topic, Combined Modality Therapy, Cytotoxicity, early breast cancer, FDA approval, Female, Humans, Immunotherapy, Metastasis, Monoclonal antibodies, Neoadjuvant Therapy, pathological complete response, Receptor, ErbB-2 - antagonists & inhibitors, Receptor, ErbB-2 - metabolism, Regulatory approval, T-DM1, Targeted cancer therapy, trastuzumab, trastuzumab emtansine, Treatment Outcome